These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 289427)

  • 1. [On the existence of a myeloproliferative factor in patients with a myeloproliferative syndrome (author's transl)].
    Essers U; Nowak H
    Blut; 1979 Aug; 39(2):107-15. PubMed ID: 289427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
    Gingold N
    Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum erythropoietin (ESF) levels and erythroid progenitors (CFU-Es) of patients with chronic myeloproliferative disorders.
    Fukushima Y; Miura I; Takahashi T; Fukuda M; Yoshida K; Yamaguchi A; Miura AB
    Tohoku J Exp Med; 1984 Apr; 142(4):399-407. PubMed ID: 6588639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases.
    Tinggaard Pedersen N; Laursen B
    Scand J Haematol; 1983 Jan; 30(1):50-8. PubMed ID: 6573016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of a myeloproliferative factor in patients with polycythemia vera and agnogenic myeloid metaplasia. I. Expansion of the erythropoietin-responsive stem cell compartment.
    Ward HP; Vautrin R; Kurnick J; Robinson WA
    Proc Soc Exp Biol Med; 1974 Oct; 147(1):305-8. PubMed ID: 4531056
    [No Abstract]   [Full Text] [Related]  

  • 6. Observations on the in vitro growth of peripheral leucocytes from patients with myeloproliferative disorders.
    Pegrum GD
    Br J Haematol; 1966 Nov; 12(6):689-96. PubMed ID: 5224278
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 11. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum beta-2-microglobulin in disorders of myeloid proliferation.
    Norfolk DR; Child JA; Roberts BE; Forbes MA; Cooper EH
    Acta Haematol; 1983; 69(6):361-8. PubMed ID: 6190339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemostasis disorders with reduced activity of the von Willebrand factor in myeloproliferative syndromes].
    Leupin L; Beck EA; Furlan M; Bucher U
    Schweiz Med Wochenschr; 1983 May; 113(19):713-6. PubMed ID: 6603016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders.
    Hasselbalch H; Clemmensen I
    Scand J Clin Lab Invest; 1987 Sep; 47(5):429-33. PubMed ID: 3477850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phagocytosis in myeloproliferative disorders.
    Corberand J; LaHarrague P; De Larrard B; Nguyen F; Pris J
    Am J Clin Pathol; 1980 Sep; 74(3):301-5. PubMed ID: 6932175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular growth factors in polycythemia vera and other myeloproliferative disorders.
    Eid J; Ebert RF; Gesell MS; Spivak JL
    Proc Natl Acad Sci U S A; 1987 Jan; 84(2):532-6. PubMed ID: 3467372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels in normal, pathological, and foetal sera of the three transcobalamins.
    Bloomfield FJ; Scott JM; Somerville JJ; Weir DG
    Ir J Med Sci; 1973 Mar; 142(2):51-7. PubMed ID: 4527886
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
    Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
    Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum erythropoietin titers in hematological malignancies and related diseases.
    Urabe A; Mitani K; Yoshinaga K; Iki S; Yagisawa M; Ohbayashi Y; Takaku F
    Int J Cell Cloning; 1992 Nov; 10(6):333-7. PubMed ID: 1460322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.